<DOC>
	<DOCNO>NCT00219323</DOCNO>
	<brief_summary>This study evaluate safety efficacy omalizumab 48 week adult patient moderate severe bronchial asthma . THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES</brief_summary>
	<brief_title>Long-Term Study IGE025 Moderate Severe Bronchial Asthma .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Allergic asthma patient Inadequately control patient History severe anaphylactoid anaphylactic reaction Previous treatment omalizumab History cancer cancer Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma , IgE , Omalizumab</keyword>
</DOC>